Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial
Hematol., Transfus. Cell Ther. (Impr.)
;
45(3): 281-289, July-Sept. 2023. tab, graf
Artículo
en Inglés
| LILACS
| ID: biblio-1514162
ABSTRACT
ABSTRACT Introduction:
This study was performed to evaluate the degree of 3-day chemotherapy-induced nausea and vomiting (CINV) in children with cancer who received highly emetogenic chemotherapy (HEC) to ascertain the efficacy of aprepitant single-dose on dayL 1 plus granisetron and dexamethasone (DEX).Methods:
This clinical trial study was conducted on 120 patients in the age range of 5 to 18 years old who received chemotherapy. Patients were divided into two groups; Group A received aprepitant at 125 mg/kg on day 1 orally, followed by 80 mg/kg daily on days 2 and 3 and Group B received a single dose of aprepitant 125 mg/kg on day 1 orally and placebo on days 2 and 3. All groups received granisetron 3 mg/m2 on day 1 and DEX on days 1 to 3. The primary and secondary endpoints were to evaluate the proportion of patients with acute, delayed and overall CINV within each group.Results:
There were no significant differences between the two groups for vomiting, nausea or the use of rescue therapy. The number of patients without vomiting on day 1 was similar in both groups (96.5% vs. 98.3%, respectively; p = 0.848).Conclusion:
According to the results of this study, a single dose of aprepitant 125 mg/kg was as effective as administering three doses of aprepitant on 3 days. Therefore, the use of a single dose of aprepitant in combination with other standard treatment regimens to prevent CINV in children who received HEC was safe and efficacious and can be beneficial.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Vómitos
/
Dexametasona
/
Granisetrón
/
Aprepitant
/
Náusea
Límite:
Adolescente
/
Niño
/
Child, preschool
/
Humanos
Idioma:
Inglés
Revista:
Hematol., Transfus. Cell Ther. (Impr.)
Asunto de la revista:
Hematologia
/
TransfusÆo de Sangue
Año:
2023
Tipo del documento:
Artículo
País de afiliación:
Irán
Institución/País de afiliación:
Arak University of Medical Sciences/IR
/
Iran University of Medical Sciences/IR
/
Khomein University of Medical Sciences/IR
/
Semnan University of Medical Sciences/IR
Similares
MEDLINE
...
LILACS
LIS